Program

Friday 6 August 2021

7:30am

Registration Open

8:30am - 8:35am Welcome & Introduction
A/Prof Nicole Goh
Melbourne, Australia
8:40am - 8:50am Australian ILD Update
A/Prof Tamera Corte
Sydney, Australia
Session Chairs:
Dr Lauren Troy
8:50am - 9:25am Imaging of fibrotic lung disease: perceptions, probabilities and likelihoods
Dr Simon Walsh
London, United Kingdom
9:25am - 9:55am PF-ILD
Dr Kerri Johannson
Calgary, Canada
9:55am - 10:25am Questions and answers

10:20am - 10:50am

Morning Tea Break

10:50am - 11:20am COVID-19 and ILD
Prof Athol Wells
London, United Kingdom
Session Chairs:
A/Prof Ian Glaspole
Dr Yet Khor
11:20am - 11:50am IPF-1 Update
Dr Kerri Johannson
Calgary, Canada
11:50am - 12:20pm Pulmonary Vasculitis
Dr Greg Keir and Dr Luke Droney
Brisbane, Australia
12:20pm - 12:35pm Questions and answers

12:35pm - 1:15pm

Lunch Break

Abstract Presenter Session

1.15pm - 1.25pm Top 10 research priorities for pulmonary fibrosis: What matters most to people living with the disease, their caregivers, healthcare professionals and researchers?
Dr Gabriella Tikellis
Session Chairs:
A/Prof Nicole Goh
Prof Paul Reynolds
1:25pm - 1:35pm Profiling of miRNA in circulating small extracellular vesicles in progressive IPF
Dr Dino Bee Aik Tan
1:35pm - 1:45pm Characterisation of the immune environment in idiopathic pulmonary fibrosis
Ms Tylah Miles
1:45pm - 1:55pm A fibrosis biomarker index for interstitial lung disease in people with systemic sclerosis: observations from an Australian multicentre cohort study.
A/Prof Tamera Corte
1:55pm - 2:05pm A novel variant in surfactant protein A2 is the likely cause of idiopathic pulmonary fibrosis in an Australian family
Dr Sionne Lucas
2:05pm - 2:15pm Interstitial Lung Disease Multidisciplinary Meeting Standardization: First round of an International Modified Delphi Survey
Dr Alan Teoh
2:15pm - 2:25pm Morphometric analysis of vascular remodelling in idiopathic pulmonary fibrosis (IPF) patients: Relation to pulmonary hypertension and endothelial to mesenchymal transition (EndMT)
Dr Mathew Eapen
2:25pm - 2:35pm Machine learning algorithm identifies key risk factors for Idiopathic Pulmonary Fibrosis progression
Dr John Mackintosh
2:35pm - 2:45pm Questions and answers

2:45pm - 3:15pm

Afternoon Tea Break

3:15pm - 3:45pm Connective tissue disease associated interstitial lung disease; where are we now, and where are we going?
Dr Adelle Jee
Sydney, Australia
Session Chairs:
Dr Alan Teoh
Dr Elizabeth Veitch
3:45pm - 4:15pm PH
Dr Melanie Lavender
Perth, Australia
4:15pm - 4:45pm Silicosis
Prof Dan Chambers
Brisbane, Australia
4:45pm - 5:00pm Questions and answers

Saturday 7 August 2021

8:00am

Registration Open

9:00am - 9:30am Dual Energy CT in Pulmonary Hypertension
Prof Johnny Vlahos
Austin, Texas
Session Chair:
A/Prof Samantha Ellis
9:30am - 10:00am Imaging of pulmonary COVID-19: current understanding
Prof Jane Ko
New York, United States
10:00am - 10:10am Questions and answers

10:10am - 10:30am

Morning Tea Break

10:30am - 11:00am Chronic hypersensitivity pneumonitis: ATS clinical practice guidelines
Dr Taryn Reddy
Brisbane, Australia
Session Chair:
Dr Amy Baker
11:00am - 11:30am Antisynthetase syndrome
A/Prof Samantha Ellis
Melbourne, Australia
11:30am - 11:40am Questions and answers

11:40am - 1:00pm

Lunch Break

1:00pm - 1:25pm Telomere Dysfunction in Lung Fibrosis: Relationship between Environmental Stressors and Disease Behaviour
Prof Paul Wolters
San Francisco, United States
Session Chairs:
Dr Jade Jaffar
A/Prof Jay Horvat
1:25pm - 1:45pm Role of aging related mechanisms in the diagnosis and pathogenesis of IPF
Prof Melanie Königshoff
Pennsylvania, United States

Abstract Presenter Session

1:45pm - 1:55pm Long-term Exposure to Ambient Air Pollutants Leads to Decreased Lung Function in Participants with Idiopathic Pulmonary Fibrosis: Analysis from the Australian IPF Registry
Dr Qiang Zheng
1:55pm - 2:05pm Iron metabolism: Role and potential for therapeutic manipulation in pulmonary fibrosis
Dr Alexandra Brown
2:05pm - 2:15pm Systemic ferritin is an early disease biomarker for silicosis patients
Dr Christian Aloe
2:15pm - 2:25pm Pre-clinical evaluation of ACT-001, an NF-kB inhibitor, in idiopathic pulmonary fibrosis (IPF)
Dr Jade Jaffar
2:25pm - 2:35pm Formyl peptide receptor agonists as novel vasodilators for pulmonary hypertension
Mr William Studley
2:35pm - 2:45pm Questions and answers

2:45pm - 3:25pm

Afternoon Tea Break

Rapid Science Session

3:25pm - 3:28pm Comparative study via RNA sequencing to investigate the shared mechanisms across skin fibrosis and pulmonary fibrosis
Ms Zhenjun Deng
Session Chairs:
Dr Jane Bourke
Dr Michale Schuliga
3:28pm - 3:31pm Mechanisms of antifibrotics in the treatment of Idiopathic Pulmonary Fibrosis
Mr Roger Li
3:31pm - 3:34pm IL-1α but not IL-33 contributes to fibroblast – immune cell cross-talk in IPF
Miss Tylah Miles
3:34pm - 3:37pm Relaxin is a potent inhibitor of ex vivo fibrogenesis in human precision cut lung slices
Ms Claudia Sim
3:37pm - 3:40pm Regulation of PD-L1 expression in mouse lung fibroblasts
A/Prof Steven Mutsaers
3:40pm - 3:43pm Angiotensin-converting enzyme 2 (ACE2), TMPRSS2 and Furin expression increases in lung tissue from idiopathic pulmonary fibrosis (IPF) and lymphangioleiomyomatosis (LAM) patients: implications for COVID -19
Dr Wenying Lu
3:43pm - 3:55pm Questions and answers
4:05pm - 4:20pm The contribution of environmental exposures to bronchiectasis in Indigenous children
Prof Graeme Zosky
Tasmania, Australia
4:20pm - 4:45pm Integrins, TGFb and Lung Tissue Remodelling
Dr Amanda Tatler
Nottingham, UK
4:45pm - 5:00pm Conference Closing